Roka Bioscience
The technology works directly from clinical samples and can potentially be multiplexed to detect tens of targets, according to the firm.
Roka Bioscience Sells Assets for $17.5M, Will Likely Liquidate
The sale of assets to the Institute for Environmental Health comes after an extensive review of strategic alternatives for Roka, the company said.
Roka Bio Q1 Revenues Rise 25 Percent
Revenue growth was driven by a 26 percent increase in the number of pathogen detection tests sold. The total number of placed Atlas instruments ticked up to 54.
Roka Bioscience Q4 Revenues Up 27 Percent
The company said it had 53 of its Atlas molecular diagnostic systems placed with customers under commercial agreements as of the end of 2016.
Roka Bioscience Q3 Revenues Up 27 Percent
The company attributed the revenue growth to an increased number of its Atlas molecular pathogen detection instruments placed with customers.
Oct 11, 2016
Roka Bioscience Plans 1-for-10 Reverse Stock Split
Aug 5, 2016
Roka Bioscience Q2 Revenues Up 20 Percent
May 4, 2016
Roka Bioscience Q1 Revenues Grow 7 Percent
Mar 4, 2016
Roka Bioscience Q4 Revenues Rise 7 Percent
Nov 11, 2015
Roka Bioscience Reports Flat Q3 Revenues
Aug 13, 2015
Roka Bio Revenues Grow 7 Percent in Q2
Mar 26, 2015
Roka Bio Reports Doubling of Q4 Revenues
Jul 17, 2014
Roka Goes Public in $60M Stock Offering
Jan 12, 2012